Avipero

MODIFYING CANCER PROGRESSION THROUGH
CELL REAIR and RESTORATION Our target was cellular repair.

AVIPERO Bio was founded by core scientific expertise with a keen interest in therapeutic disruptors in clinical indications where treatments stagnated due to misunderstood pathologies. AVIPERO Bio seeks to reimagine beta1 integrin targeting in oncology by deconvoluting its role in cancer cell behaviour. In irreversible injury and senescence models, AVIPERO identified beta1 integrin as a novel targ

et for inducing repair and regeneration and reversing aging. Targeting the non-ligand binding part of beta1 integrin to allosterically preserve the receptor in its normal low affinity state (dimmer switch), reduces matrix stiffness and cellular stress and normalises cell cycle to allow normal aging. Beta1 Integrin is crucial for tumor metastasis and increased expression is associated with decreased survival advanced cancers. Ablation of beta1 integrin
in tumor cells reduces tumor cell proliferation and the acquisition of
cellular aging. Antibodies against beta1-integrin inhibited tumour growth in mouse models of breast cancer, prostate cancer, osteosarcoma and melanoma. Anti-beta1 integrin antibody inhibits metastasis of breast cancer.

18/06/2025

Avipero Bio Forms Scientific Advisory Board, Appoints Dr. Azmi Nabulsi as Chairman

Avipero Bio today announced the formation of its Scientific Advisory Board (SAB) with the appointment of Dr. Azmi Nabulsi as Chairman. Dr. Nabulsi brings over 25 years of clinical development experience in biopharmaceutical innovation, having led programs from discovery through global regulatory approval.
He previously held senior roles at Takeda Pharmaceuticals and Abbott Laboratories, and currently serves as Entrepreneur-in-Residence at Frazier Life Sciences. His leadership will guide Avipero Bio as it advances its therapeutic platform toward impactful breakthroughs.
We are thrilled to welcome Dr. Nabulsi. His deep expertise in translational medicine and biotech innovation will be instrumental in shaping our scientific strategy.

31/03/2025

Join our new CEO and AVIPERO Bio’ talented team on our quest to revolutionise cancer metastasis treatment.

I am assuming the role of CEO of AVIPERO Bio. Join us in our quest to develop our revolutionary therapeutic for metastastic cancers by taming its behavior rather than killing!

11/03/2025

02/01/2025

Avipero is celebrating the start of the new year with the appointment of Dr Osama Nabulsi on our unique venture. As a non-executive board member, Osama brings a unique blend of strategic vision, analytical rigor, and industry knowledge, making him an invaluable advisor for organizations seeking to navigate the evolving healthcare environment and capitalize on growth opportunities. His experience in both operational and strategic roles equips him to provide balanced, insightful governance and support in board decision-making.

01/10/2024

14/09/2024

It is with great pleasure we announce the appointment of Mr Mark Radford to the board of Avipero Bio. This comes after the significant addition of Dr. Ian Smith as Chief Medical Officer. The new members of the team bring a wealth of international leadership experience in biotechnology, public health and clinical drug development.

Address

Edinburgh

Website

http://www.avipero.com/

Alerts

Be the first to know and let us send you an email when Avipero posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Avipero: